NCT07154381 Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis
| NCT ID | NCT07154381 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Essen |
| Condition | Cardiac Amyloidosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2019-12-09 |
| Primary Completion | 2025-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2019-12-09 with a primary completion date of 2025-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).
Eligibility Criteria
Inclusion Criteria: * Age \> 40 years * proven Amyloidosis (ATTR or AL) * Women: negative pregnancy test less than weeks prior imaging. Exclusion Criteria: * Patients receiving amyloidosis-specific treatment prior study inclusion. * Patients participating in other clinical trails for treatment of Amyloidosis. * Pregnancy * Contraindiactions for MRI (eGFR\<30ml/min/1.73m2; gadolinium allergy; metallic implants or device not suited for 3T MRI). * inability of consent * Refusal of consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07154381 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Cardiac Amyloidosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07154381 currently recruiting?
Yes, NCT07154381 is actively recruiting participants. Contact the research team at david.kersting@uk-essen.de for enrollment information.
Where is the NCT07154381 trial being conducted?
This trial is being conducted at Essen, Germany.
Who is sponsoring the NCT07154381 clinical trial?
NCT07154381 is sponsored by University Hospital, Essen. The trial plans to enroll 25 participants.